Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetic kidney disease (DKD) is a major complication of diabetes mellitus, significantly impacting patient morbidity and mortality.
• Oral hypoglycemic agents, including dipeptidyl peptidase 4 (DPP-4) inhibitors, are used to manage glycemic control and may influence DKD.
• DPP-4 inhibitors target the incretin system and have demonstrated pleiotropic effects in preclinical studies.

Purpose of the Study:

• To review the potential kidney protective effects of DPP-4 inhibitors in the context of diabetic kidney disease.
• To evaluate the current evidence regarding the impact of DPP-4 inhibitors on DKD progression.

Main Methods:

• Review of existing clinical trials and in vitro studies on DPP-4 inhibitors and kidney outcomes.
• Analysis of the mechanisms by which DPP-4 inhibitors may exert renoprotective effects.

Main Results:

• DPP-4 inhibitors show potential in vitro benefits, including reduced inflammation, fibrosis, and oxidative stress.
• Current clinical trial data suggest a possible role for DPP-4 inhibitors in slowing DKD progression.
• Further investigation is required to establish definitive kidney-specific advantages.

Conclusions:

• DPP-4 inhibitors represent a therapeutic class with potential pleiotropic effects beneficial for kidney health in diabetic patients.
• While preliminary evidence is encouraging, robust clinical data are necessary to confirm the renoprotective efficacy of DPP-4 inhibitors.
• The role of DPP-4 inhibitors in managing diabetic kidney disease warrants continued research and clinical evaluation.